Peptides by condition · Hormones and sexual health
Peptides studied for growth hormone deficiency
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 7 study pages on growth hormone deficiency: 6 in people (5 of them meta-analyses or randomized trials), and 1 in animals. They studied 3 compounds, with this many study pages each: HGH 5, MK-677 1 and CJC-1295 with DAC 1.
What the research on growth hormone deficiency looks like
Growth hormone deficiency means the pituitary gland, at the base of the brain, makes too little growth hormone. In children it slows growth in height; in adults it can bring more body fat, less muscle and weaker bones. The studies here are mostly in children and test lab-made growth hormone, given as a daily shot or in newer weekly forms, and one pill that makes the body release more of its own.
Trials in children measure height velocity, how many centimeters a child grows in a year, against the child’s own rate before the shots began or against daily growth hormone. Studies in adults measure IGF-1, a blood hormone that rises with growth hormone.
Most of these trials compared a weekly form with daily growth hormone rather than with placebo, so they show whether it keeps up, not whether growth hormone acts at all. Look at whether the children were before puberty, since growth speeds up in puberty on its own.

The 7 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
HGH
5 in peopleFor growth hormone deficiency, 5 of our study pages are filed under HGH: 1 meta-analysis, 3 randomized trials and 1 clinical trial in people. The largest in people pooled 1,393 people and was published in 2025. They were published from 1987 to 2025, in Sci Rep, J Clin Endocrinol Metab, Horm Res Paediatr and Acta Paediatr Scand Suppl.
FDA-approved, with a use tied to growth hormone deficiency on its label: Humatrope (injection) for growth failure in children who make too little growth hormone and several other causes of short stature, and growth hormone deficiency in adults.
- Meta-analysis in people · 1,393 people · 2025HGH: long-acting PEG form beat daily HGH on height at 12 months
- Randomized trial in people · 391 people · 2025HGH: weekly Pegpesen matched daily rhGH on growth in children
- Randomized trial in people · 228 people · 2022HGH: 9.78 cm/year growth vs 10.10 on weekly somatrogon
- Randomized trial in people · 44 people · 2022HGH: weekly somatrogon 9.65 vs daily 7.87 cm/year in GHD children
- Clinical trial in people · 47 people · 1987HGH: growth rate rose from 4.2 to 13.9 cm/year in children
MK-677
1 in peopleFor growth hormone deficiency, 1 of our study pages is filed under MK-677: 1 randomized trial in people. It enrolled 9 people and was published in 1997, in J Clin Endocrinol Metab.
MK-677 (ibutamoren) has no FDA-approved product: Drugs@FDA lists no application for it.
- Randomized trial in people · 9 people · 1997MK-677: IGF-I rose 52% at 10 mg and 79% at 50 mg in GH-deficient men
CJC-1295 with DAC
1 in animalsFor growth hormone deficiency, 1 of our study pages is filed under CJC-1295 with DAC: 1 animal study (mice). It was published in 2006, in Am J Physiol Endocrinol Metab.
CJC-1295 has no FDA-approved product: Drugs@FDA lists no application for it.
- Animal study in mice · 2006CJC-1295 with DAC daily normalized growth in GHRH knockout mice
Side by side
For the 3 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| HGH | 5 | 0 | 1,393 | Approved, a use tied to it |
| MK-677 | 1 | 0 | 9 | Not approved |
| CJC-1295 with DAC | 0 | 1 | — | Not approved |
- In people
- 5
- Animals or cells
- 0
- Largest in people
- 1,393
- FDA
- Approved, a use tied to it
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 9
- FDA
- Not approved
- In people
- 0
- Animals or cells
- 1
- Largest in people
- —
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- HGH: long-acting PEG form beat daily HGH on height at 12 monthsThe pooled studies mixed randomized trials with cohort studies, and only the standard PEG-rhGH dose was compared. The side effect comparison came from the randomized trials alone.
- HGH: weekly Pegpesen matched daily rhGH on growth in childrenThe trial lasted 52 weeks and was run only in China, so it doesn't show effects on final adult height or longer-term safety. It tested children with GHD, not adults or other uses of growth hormone.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for growth hormone deficiency?
Our 7 study pages on growth hormone deficiency are filed under 3 compounds, with this many each: HGH 5, MK-677 1 and CJC-1295 with DAC 1. HGH has the most.
Have any been tested in people with growth hormone deficiency?
Yes: 6 of the 7 were in people, 5 of them meta-analyses or randomized trials (HGH and MK-677). The largest pooled 1,393 people: “HGH: long-acting PEG form beat daily HGH on height at 12 months” (2025).
Is any peptide FDA-approved for growth hormone deficiency?
Yes, with a use tied to growth hormone deficiency on their FDA labels: HGH as Humatrope. 2 other compounds here with an FDA record have no use tied to it.
How large were the studies in people on growth hormone deficiency?
Of the 6 in people, all give their size on our pages: 1 had 1,000 people or more, 2 had 100 to 999 and 3 had fewer than 100. The largest, a meta-analysis from 2025, pooled 1,393.
What did the animal and cell studies on growth hormone deficiency use?
1 animal study (mice), filed under CJC-1295 with DAC. A result in animals or cells shows what to test next, not what happens in a person.
What is the newest study on growth hormone deficiency here?
Of our study pages on growth hormone deficiency, the newest is “HGH: long-acting PEG form beat daily HGH on height at 12 months”, a meta-analysis in people published in 2025.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.